Northern Trust Corp boosted its holdings in Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 9.5% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 187,017 shares of the company's stock after purchasing an additional 16,299 shares during the quarter. Northern Trust Corp owned about 0.63% of Disc Medicine worth $11,857,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Sterling Capital Management LLC boosted its holdings in Disc Medicine by 798.4% in the fourth quarter. Sterling Capital Management LLC now owns 566 shares of the company's stock valued at $36,000 after purchasing an additional 503 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in Disc Medicine by 47.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 825 shares of the company's stock valued at $52,000 after purchasing an additional 266 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in Disc Medicine in the fourth quarter valued at approximately $235,000. Teacher Retirement System of Texas boosted its holdings in Disc Medicine by 8.9% in the fourth quarter. Teacher Retirement System of Texas now owns 4,857 shares of the company's stock valued at $308,000 after purchasing an additional 396 shares in the last quarter. Finally, Virtu Financial LLC acquired a new stake in shares of Disc Medicine in the fourth quarter valued at approximately $309,000. 83.70% of the stock is owned by institutional investors and hedge funds.
Disc Medicine Stock Performance
IRON stock opened at $48.09 on Friday. Disc Medicine, Inc. has a one year low of $30.65 and a one year high of $68.73. The stock has a market capitalization of $1.66 billion, a PE ratio of -12.08 and a beta of 0.77. The company has a fifty day moving average of $46.10 and a 200-day moving average of $54.88.
Disc Medicine (NASDAQ:IRON - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.99) by ($0.03). Equities analysts forecast that Disc Medicine, Inc. will post -4.07 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several equities research analysts have recently weighed in on IRON shares. BMO Capital Markets increased their price objective on Disc Medicine from $112.00 to $120.00 and gave the company an "outperform" rating in a report on Monday, May 12th. Cantor Fitzgerald increased their price objective on Disc Medicine from $99.00 to $132.00 and gave the company an "overweight" rating in a report on Tuesday, March 18th. Scotiabank increased their price objective on Disc Medicine from $73.00 to $75.00 and gave the company a "sector outperform" rating in a report on Monday, March 3rd. HC Wainwright reissued a "buy" rating and issued a $118.00 price objective on shares of Disc Medicine in a report on Tuesday, January 21st. Finally, Wedbush reissued an "outperform" rating and issued a $90.00 price objective (up from $83.00) on shares of Disc Medicine in a report on Tuesday, January 21st. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $98.80.
Read Our Latest Stock Analysis on IRON
Insider Transactions at Disc Medicine
In other news, insider Pamela Stephenson sold 3,137 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $54.58, for a total value of $171,217.46. Following the completion of the transaction, the insider now owns 69,529 shares in the company, valued at $3,794,892.82. This trade represents a 4.32% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider William Jacob Savage sold 2,100 shares of the stock in a transaction dated Friday, May 2nd. The shares were sold at an average price of $50.17, for a total transaction of $105,357.00. Following the completion of the transaction, the insider now owns 66,398 shares of the company's stock, valued at $3,331,187.66. This represents a 3.07% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 356,290 shares of company stock worth $19,336,901. Company insiders own 4.24% of the company's stock.
About Disc Medicine
(
Free Report)
Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
Featured Stories
Want to see what other hedge funds are holding IRON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Disc Medicine, Inc. (NASDAQ:IRON - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Disc Medicine, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Disc Medicine wasn't on the list.
While Disc Medicine currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
